p53 and mdm-2 expression in rhabdomyosarcoma of childhood and adolescence: Clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study

Pediatric and Developmental Pathology

Volumn 6, Issue 2, 2003, Pages 128-136

  Leuschner, Ivo ^a   Langhans, Inken ^a   Schmitz, Regina ^a   Harms, Dieter ^a   Mattke, Adrian ^b   Treuner, Jörn ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b OLGAHOSPITAL   (Germany)

Author keywords

Ki 67; Mdm 2; Metastasis; P53; Prognosis; Rhabdomyosarcoma

Indexed keywords

KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; ANTIBODY LABELING; ARTICLE; CANCER REGISTRY; CELL COUNT; CELL PROLIFERATION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS; MITOSIS RATE; ONCOGENE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; KI-67 ANTIGEN; MALE; MITOSIS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; SOFT TISSUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037360842     PISSN: 10935266     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10024-001-0097-z     Document Type: Article

References (43)

1. Croce CM, Isobe M, Emanuel BS, Givol D, Oren M. Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986;320:84-85.
2. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
3. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
5. Resnick-Silverman L, St. Clair S, Maurer M, Zhao K, Manfredi JJ. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 1998;12:2102-2107.
6. Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol 1999;10:1011-1021.
7. Würl P, Meye A, Schmidt H, et al. High prognostic significance of mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 1998;16:1183-1185.
8. Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI. p53 gene mutations and p53 expression in human soft tissue sarcomas. Arch Pathol Lab Med 1997;121:395-399.
9. Kawai A, Noguchi M, Beppu Y, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. Cancer 1994;73:2499-2505.
10. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 1990;87:5863-5867.
11. Würl P, Taubert H, Bache M, et al. Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors (Abstract). Int J Cancer 1996;69:317-323.
12. Kusafuka T, Fukuzawa M, Oue T, Komoto Y, Yoneda A, Okada A. Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg 1997;32:1175-1180.
13. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995;95:1606-1611.
14. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992;52:2243-2247.
15. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-1304.
16. Ayan I, Dogan O, Kebudi R, et al. Immunohistochemical detection of p53 protein in rhabdomyosarcoma: association with clinicopathological features and outcome. J Pediatr Hematol Oncol 1997;19:48-53.
17. Momand J, Wu HH, Dasgupta G. mdm2 - master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
18. Momand J, Jung D, Wilczynski S, Niland J. The mdm2 gene amplification database. Nucleic Acids Res 1998;26:3453-3459.
19. Waber PG, Chen J, Nisen PD. Infrequency of mdm2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 1993;53:6028-6030.
20. Drobnjak M, Latres E, Pollack D, et al. Prognostic implications of p53 nuclear overexpression and high proliferation index in adult soft-tissue sarcomas. J Natl Cancer Inst 1994;86:549-554.
21. Hilton DA, Love S, Barber R. Demonstration of apoptotic cells in tissue sections by in situ hybridization using digoxigenin-labeled poly(A) oligonucleotide probes to detect thymidine-rich DNA sequences. J Histochem Cytochem 1997;45:13-20.
22. Donaldson SS, Draper GJ, Flamant F, Gerard-Marchant R, Newton WA, Lemerle J. Topography of childhood tumors: pediatric coding system. Pediatr Hematol Oncol 1986;3:249-258.
23. Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification. An Intergroup Rhabdomyosarcoma Study. Cancer 1995;76:1073-1085.
24. Hsu SM, Raine L, Fanger HJ. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody PAP procedures. Histochem Cytochem 1981;29:577-580.
25. Hsu SM, Soban E. Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J Histochem Cytochem 1982;30:1079-1082.
26. Norton AJ, Jordan S, Yeoman P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994;173:371-379.
27. Rodary C, Flamant F, Donaldson SS. An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP). Med Pediatr Oncol 1989;17:210-215.
28. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study - I. A final report. Cancer 1988;61:209-220.
29. de Alava E, Antonescu CR, Panzio A, et al. Prognostic impact of p53 status in Ewing sarcoma. Cancer 2000;89:783-792.
30. McKee PH, Hobbs C, Hall PA. Antigen retrieval by microwave irradiation lowers immunohistochemical detection tresholds. Histopathology 1993;23:377-379.
31. Di Leonardi A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994;8:2540-2551.
32. Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M. The mdm2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 1996;149:143-151.
33. Boman F, Brel D, Antunes L, Alhamany Z, Floquet J, Boccon-Gibod L. Gene alterations and apoptosis in rhabdomyosarcoma. Pediatr Pathol Lab Med 1997;17:233-247.
34. Harms D. Alveolar rhabdomyosarcoma: a prognostically unfavorable rhabdomyosarcoma type and its necessary distinction from embryonal rhabdomyosarcoma. In: Harms D, Schmidt D, eds. Current Topics in Pathology, vol. 89: Soft Tissue Tumors. Berlin: Springer-Verlag, 1995;273-296.
35. Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 1999;17:3706-3719.
36. Yap DBS, Hsieh JK, Chan FSG, Lu X. mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 1999;18:7681-7689.
37. Meddeb M, Valent A, Danglot G, et al. MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Cytogenet Cell Genet 1996;73:325-330.
38. Jensen V, Brandt Sorensen F, Bentzen SM, et al. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistochemical study including 216 soft tissue sarcomas. Histopathology 1998;32:536-546.
39. Choong PF, Akerman M, Willen H, et al. Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation - a marker of metastasis? APMIS 1994;102:915-924.
40. Jensen V, Hoyer M, Sorensen FB, Keller J, Jensen OM. MIB-1 expression and iododeoxyuridine labelling in soft tissue sarcomas: an immunohistochemical study including correlations with p53, bcl-2 and histological characteristics. Histopathology 1996;28:437-444.
41. Pindzola JA, Palazzo JP, Kovatich AJ, Tuma B, Nobel M. Expression of p21 WAF1/CIP1 in soft tissue sarcomas: a comparative immunohistochemical study with p53 and Ki-67. Pathol Res Pract 1998;194:685-691.
42. Kreipe H, Wacker HH, Heidebrecht HJ, et al. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 1993;142:1689-1694.
43. Heidebrecht HJ, Buck F, Haas K, Wacker HH, Parwaresch R. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki-67' proteins. Cell Prolif 1996;29:413-425.